Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of INO-4800 COVID-19 Vaccine
NCT04336410Phase 1Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Apr 2020
- Primary completion
- Feb 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of INO-4800 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Inovio Pharmaceuticals, Inc. Primary endpoints: Percentage of Participants with Adverse Events, Percentage of Participants with Administration (Injection) Site Reactions and 3 more. Started Apr 2020; status: completed.
02
Drugs
INO-4800
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04336410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04336410.